Improvement in the survival rates of extracorporeal membrane oxygenation-supported respiratory failure patients: a multicenter retrospective study in Korean patients by Baek, Moon Seong et al.
RESEARCH Open Access
Improvement in the survival rates of
extracorporeal membrane oxygenation-
supported respiratory failure patients: a
multicenter retrospective study in Korean
patients
Moon Seong Baek1†, Sang-Min Lee2†, Chi Ryang Chung3, Woo Hyun Cho4, Young-Jae Cho5, Sunghoon Park6,
So-My Koo7, Jae-Seung Jung8, Seung Yong Park9, Youjin Chang10, Byung Ju Kang11, Jung-Hyun Kim12,
Jin Young Oh13, So Hee Park14, Jung-Wan Yoo15, Yun Su Sim16 and Sang-Bum Hong1*
Abstract
Background: Although the utilization of extracorporeal membrane oxygenation (ECMO) is increasing and its
technology is evolving, only a few epidemiologic reports have described the uses and outcomes of ECMO.
The aim of this study was to investigate the changes in utilization and survival rate in patients supported
with ECMO for severe respiratory failure in Korea.
Methods: This was a multicenter study on consecutive patients who underwent ECMO across 16 hospitals in
Korea. The records of all patients who required ECMO for acute respiratory failure between 2012 and 2015
were retrospectively reviewed, and the utilization of ECMO was analyzed over time.
Results: During the study period, 5552 patients received ECMO in Korea as a whole, and a total of 2472 patients
received ECMO at the participating 16 hospitals. We analyzed 487 (19.7%) patients who received ECMO for
respiratory failure. The number of ECMO procedures provided for respiratory failure increased from 104 to 153
during the study period. The in-hospital survival rate increased from 30.8% to 35.9%. The use of prone positioning
increased from 6.8% to 49.0% (p < 0.001), and the use of neuromuscular blockers also increased from 28.2% to 58.2%
(p < 0.001). Multiple regression analysis showed that old age (OR 1.038 (95% CI 1.022, 1.054)), use of corticosteroid
(OR 2.251 (95% CI 1.153, 4.397)), continuous renal replacement therapy (OR 2.196 (95% CI 1.135, 4.247)), driving
pressure (OR 1.072 (95% CI 1.031, 1.114)), and prolonged ECMO duration (OR 1.020 (95% CI 1.003, 1.038)) were
associated with increased odds of mortality.
Conclusions: Utilization of ECMO and survival rates of patients who received ECMO for respiratory failure increased
over time in Korea. The use of pre-ECMO prone positioning and neuromuscular blockers also increased during the
same period.
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Background
Extracorporeal membrane oxygenation (ECMO), which
provides respiratory and/or cardiac support, allows treat-
ment of patients with refractory gas-exchange abnormal-
ities [1]. The use of ECMO to support patients with
respiratory failure is increasing worldwide following the
use of ECMO for severe acute respiratory failure during
the 2009 influenza A pandemic [2–5]. Recently, the
EOLIA trial reported that in patients with severe acute
respiratory distress syndrome (ARDS) there was no sig-
nificant difference in 60-day mortality between patients
who received early ECMO and those who received con-
ventional mechanical ventilation that included ECMO as
rescue therapy [6]. However, crossover to ECMO oc-
curred in 28% of patients in the conventional group,
who showed a high mortality rate of 57%. This suggests
that ECMO can be used in severe ARDS patients who
do not benefit from conventional treatment.
Survival of patients who received ECMO is also grad-
ually increasing over time [7]. A recent epidemiologic
report in Germany showed that ECMO utilization for
severe respiratory failure significantly increased from
2007 until 2012, and in-hospital survival increased over
time as well [8]. Sauer et al. [9] reported that the annual
rates of ECMO cases increased by 433% from 2006 to
2011 in the United States, and that, albeit not statisti-
cally significant, there was an improving trend in the
survival rate as well. In a single-center study in Korea,
the survival rates associated with the ECMO procedure
increased between 2009 and 2011 [10]. However, as we
have previously reported, there was a discrepancy in the
survival rate between those of the Extracorporeal Life
Support Organization (ELSO) registry and Korean ECMO
patients [11]. The in-hospital survival rate of ECMO-
treated patients with acute respiratory failure was 46%
from 2014 to 2015 in Korea, whereas the survival rate was
58% in the ELSO registry patients [7]. Also, we have sug-
gested that age is an important factor in the survival of pa-
tients who received ECMO. Therefore, we sought to
determine whether there has been an improvement in the
survival rate of patients who received ECMO support for
acute respiratory failure in Korea. Specifically, we evalu-
ated the changes over time in the survival rates of patients
supported with ECMO for severe respiratory failure and
the factors associated with the survival rate.
Methods
Study design
This was a multicenter study of consecutive patients
who received ECMO at 16 hospitals in Korea. The records
of all patients who required ECMO for acute respiratory
failure between 2012 and 2015 were retrospectively
reviewed and the utilization of ECMO was analyzed
over time. The decision to use ECMO was made at the
discretion of the attending physicians at each center
without standardization. The study protocol was ap-
proved by the institutional review board of Asan Med-
ical Center, and by the local institutional review boards
of all other participating centers. The requirement for
informed consent was waived due to the retrospective
design of the study.
Data collection
Data were collected from electronic medical records of
patients older than 19 years who received ECMO sup-
port. Included variables were as follows: demographic
information, Acute Physiology and Chronic Health
Evaluation (APACHE) II and Sequential Organ Failure
Assessment (SOFA) scores at intensive care unit (ICU)
admission, etiology of respiratory failure, cardiac arrest,
immunocompromised status, central nervous system
(CNS) dysfunction, pre-ECMO hemodynamic data,
mechanical ventilation parameters, and arterial blood
gas data. Immunocompromised status and CNS dysfunc-
tion were defined according to the RESP study [12].
Immunocompromised status included hematological
malignancies, solid tumors, solid-organ transplantation,
high-dose or long-term corticosteroid and/or immuno-
suppressant use, and human immunodeficiency virus
infection. CNS dysfunction included diagnoses of neu-
rotrauma, stroke, encephalopathy, cerebral embolism,
seizure, and epileptic syndrome. We collected informa-
tion on adjunctive therapy such as the use of vasopres-
sors, steroids, continuous renal replacement therapy
(CRRT), prone positioning, nitric oxide, bicarbonate in-
fusion, and neuromuscular blockers. We also collected
data such as the ECMO mode, ECMO duration, dur-
ation of mechanical ventilation to ECMO initiation,
hospital stay, and tracheotomy. The ECMO mode was
categorized as veno-venous, veno-arterial, and veno-ar-
teriovenous. Outcome variables of the study were sur-
vival at discharge and ECMO weaning (survival within
48 h after weaning from ECMO).
Statistical analysis
Demographics, pre-ECMO parameters, and outcomes
were compared between 2012 and 2015. Differences
with p < 0.05 were considered statistically significant.
Categorical variables are expressed as the number (per-
centage). Continuous variables are expressed as the me-
dian (interquartile range). Pearson’s chi-square test or
Fisher’s exact test was used to compare categorical data.
The Kruskal–Wallis test was used to compare medians
between groups.
Multiple logistic regression analysis using the back-
ward elimination method was performed to identify the
factors associated with survival at discharge. Candidate
variables for inclusion in the multiple logistic regression
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model were chosen from the univariate analysis; vari-
ables with p < 0.1 in the univariate analyses were in-
cluded in the multivariate analysis, and collinearity was
assessed before the multivariate analysis. Calibrations
of the models were evaluated with the Hosmer–Leme-
show goodness-of-fit test. Statistical analyses were per-
formed using the Statistical Package for the Social
Sciences (SPSS) version 22.0 (IBM Corporation, Armonk,
NY, USA).
Results
Baseline characteristics of the study population
During the study period (2012–2015), 5552 patients re-
ceived ECMO support in Korea. ECMO support was
given to 2472 patients in the participating 16 hospitals.
We analyzed 487 (19.7%) patients who received ECMO
specifically for respiratory failure. The annual number of
ECMO cases at 16 institutions varied widely: eight cen-
ters had fewer than 20 cases per year and the other eight
Table 1 Baseline characteristics of patients supported with ECMO
for respiratory failure
Variable Total (n = 487)
Age (years) 58 (45, 66)
Male 321 (65.9)
Body mass index (kg/m2) 22.2 (20.6, 23.2)
APACHE II score 21 (15, 28)
SOFA score 8 (5, 12)
PRESERVE score 5 (4, 6)
RESP score 0 (−2, 2)
Etiology of ARF
Viral pneumonia 47 (9.7)
Bacterial pneumonia 127 (26.1)
COPD and asthma 8 (1.6)
Trauma and burn 25 (5.1)
Asphyxia 13 (2.7)
Acute exacerbation of ILD 61 (12.5)
Chronic respiratory failure 24 (4.9)
ARDS 44 (9.0)
Airway obstruction 28 (5.7)
Other respiratory failure 110 (22.6)
Immunocompromiseda 122 (25.2)
CNS dysfunctionb 24 (5.0)
Vasopressor 301 (63.0)
Corticosteroid 82 (16.8)
Cardiac arrest 74 (15.2)
CRRT 83 (17.0)
Mechanical ventilation 449 (92.2)
Prone positioning 143 (29.5)
Pre-ECMO rescue therapy
Nitric oxide 127 (26.2)
Bicarbonate infusion 53 (11.0)
Neuromuscular blocker 230 (45.4)
Vital signs
MAP (mmHg) 70 (58, 84)
Heart rate (/min) 112 (95, 128)







pH 7.28 (7.17, 7.38)
PaO2 (mmHg) 61 (51, 76)
PaCO2 (mmHg) 51 (39, 65)
Table 1 Baseline characteristics of patients supported with ECMO
for respiratory failure (Continued)
Variable Total (n = 487)
HCO3
− (mEq/L) 23 (19, 29)
SaO2 (%) 88 (79, 93)
Ventilation parameters
PaO2/FiO2 65 (53, 90)
FiO2 100 (90, 100)
PEEP (cmH2O) 10 (6, 12)
PIP (cmH2O) 28 (24, 32)
Tidal volume (ml/kg) 7 (6, 9)
Driving pressure (cmH2O) 18 (15, 24)
Minute ventilation (L/min) 9.6 (7.4, 12.4)
Interval MV–ECMO (days) 1 (0, 5)
ECMO duration (days) 8 (4, 18)
Hospital stay (days) 35 (18, 61)
Tracheostomy 199 (41.8)
Weaning rate 278 (57.1)
Survival rate 189 (38.8)
Values expressed as median (interquartile range) or n (%)
ECMO extracorporeal membrane oxygenation, APACHE Acute Physiology and
Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment,
PRESERVE Predicting Death for Severe Acute Respiratory Distress Syndrome on
Veno-venous ECMO, RESP Respiratory Extracorporeal Membrane Oxygenation
Survival Prediction, ARF acute respiratory failure, ARDS acute respiratory
distress syndrome, COPD chronic obstructive pulmonary disease, ILD interstitial
lung disease, CNS central nervous system, CRRT continuous renal replacement
therapy, MAP mean arterial pressure, PaO2 partial pressure of arterial oxygen,
PaCO2 partial pressure of arterial carbon dioxide, HCO3
− bicarbonate, SaO2
oxygen saturation, FiO2 fraction of inspired oxygen, PEEP positive end-
expiratory pressure, PIP peak inspiratory pressure, MV mechanical ventilation
a“Immunocompromised” included hematological malignancies, solid tumors,
solid-organ transplantation, high-dose or long-term corticosteroid and/or
immunosuppressant use, and human immunodeficiency virus infection
b“CNS dysfunction” included diagnoses of neurotrauma, stroke,
encephalopathy, cerebral embolism, seizure, and epileptic syndrome
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centers had more than 30 cases per year, with two of
those centers having had more than 120 cases per year.
The patients’ median age was 58 years (range 45–66
years), and the median body mass index was 22.2 kg/m2
(range 20.6–23.2 kg/m2). Pre-ECMO mechanical venti-
lation was provided in 92.2% of patients and cortico-
steroid therapy was used in 16.8% of patients. Prone
positioning was applied in 29.5% of patients and neuro-
muscular blockers were used in 45.4% of patients. The
majority of patients were initially supported with
veno-venous ECMO (88.1%), and the median duration
of support was 8 days (interquartile range (IQR) 4, 18
days). Survival and weaning rates were 38.8% and
57.1%, respectively (Table 1).
Demographics, pre-ECMO parameters, and outcomes over
time
The number of ECMO procedures for respiratory failure
increased from 104 to 153 during the study period
(Fig. 1). There were no significant differences in age, sex,
APACHE II score, SOFA score, immunocompromised
status, CNS dysfunction, cardiac arrest, CRRT, use of ni-
tric oxide and bicarbonate infusion, PaO2/FiO2 ratio,
ECMO duration, and duration of mechanical ventilation
to ECMO initiation between groups. Use of prone posi-
tioning increased from 6.8% to 49.0% (p < 0.001) and the
use of neuromuscular blockers also increased from
28.2% to 58.2% (p < 0.001; Table 2). Although the sur-
vival rate remained relatively low, it increased over time
from 30.8% to 35.9% (p = 0.005; Table 3). Post-hoc ana-
lysis showed that the survival rate in 2014 was signifi-
cantly higher than the rates in 2012 and 2015.
Factors associated with mortality in patients supported
with ECMO
Multiple regression analysis was performed using age,
sex, year, APACHE II score, SOFA score, immunocom-
promised status, CNS dysfunction, corticosteroid, CRRT,
prone positioning, nitric oxide, neuromuscular blocker,
PaCO2, peak inspiratory pressure, driving pressure,
and ECMO duration. Old age (OR 1.038 (95% CI
1.022, 1.054)), use of corticosteroid (OR 2.251 (95% CI
1.153, 4.397)), CRRT (OR 2.196 (95% CI 1.135, 4.247)),
driving pressure (OR 1.072 (95% CI 1.031, 1.114)), and
prolonged ECMO duration (OR 1.020 (95% CI 1.003,
1.038)) were associated with increased odds of mortal-
ity (Table 4).
The median age was older in the nonsurvivors (61
years; IQR 52, 69 years) than in survivors (51 years; IQR
37, 62 years) (p < 0.001). The survival rate decreased with
age, with patients older than 60 years having a survival
rate of 30.8% (Fig. 2). ECMO duration was significantly
longer in the nonsurvivors (9 days; interquartile range
(IQR) 4, 22 days) than in survivors (7 days; IQR 3, 13
days) (p = 0.002). Compared with the survival rate within
2 weeks of ECMO support, the overall survival rate after
2 weeks of ECMO support showed a significant decrease
from 43.4% to 27.8% (p = 0.001).
Discussion
This multicenter study was conducted to evaluate the
change in survival rates of patients who received ECMO
support for acute respiratory failure in Korea. Utilization
of ECMO for respiratory failure increased over time, and
the survival rate was improved with increasing use of ad-
junctive management. Also, patient age and the duration
of ECMO were significantly associated with survival.
A notable change during the study period was that the
administration of neuromuscular blockades and use of
prone positioning before ECMO had significantly in-
creased from 28.2% to 58.2% and from 6.8% to 49.0%,
respectively. Papazian et al. [13] reported that early use
of neuromuscular blockades in patients with severe
ARDS may improve survival. In the ELSO registry-based
RESP study, neuromuscular blockade agents before
ECMO were independently associated with hospital sur-
vival [12]. In addition, in patients with severe ARDS,
early application of prolonged prone positioning was
Fig. 1 Number of ECMO procedures and weaning and survival rates of patients who received ECMO for acute respiratory failure. ECMO extracorporeal
membrane oxygenation
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significantly associated with improved survival [14].
Schmidt et al. [15] demonstrated that use of prone posi-
tioning before ECMO was also associated with survival.
These results are in accordance with those in a recent
systematic review and meta-analysis [16]. Moreover, for
patients with severe ARDS, prone positioning before and
during ECMO may be helpful for weaning from ECMO
[17, 18]. Another distinctive finding was the change in
pre-ECMO ventilator parameters. In recent years, the
driving pressure was lower and minute ventilation was
decreased. Therefore, improvement in hospital survival
of ECMO-supported patients with respiratory failure
might be the result of increasing experience with ECMO
over time, including evolving adjuvant therapies and im-
proved management of mechanical ventilation.
The results of this study showed that the number of
ECMOs carried out for respiratory failure increased
from 104 to 153 from 2012 to 2015, and that the in-hos-
pital survival rate increased from 30.8% to 35.9% during
the same period. The overall survival rate of 39% in
Table 2 Demographic features of survivors and nonsurvivors supported with ECMO for respiratory failure
Variable 2012 (n = 104) 2013 (n = 100) 2014 (n = 130) 2015 (n = 153) p value
Age (years) 59 (49, 69) 60 (45, 68) 58 (43, 66) 57 (45, 63) 0.199
Male 69 (66.3) 71 (71.0) 93 (71.5) 88 (57.5) 0.050
Body mass index (kg/m2) 22.6 (20.4, 24.6) 22.9 (19.7, 25.0) 22.1 (21.0, 22.9) 22.0 (20.5, 22.9) 0.073
APACHE II score 21 (16, 27) 22 (16, 29) 21 (15, 30) 19 (14, 26) 0.162
SOFA score 8 (5, 12) 8 (5, 11) 8 (5, 12) 8 (6, 12) 0.842
PRESERVE score 5 (4, 7) 6 (4, 7) 5 (3, 6) 5 (3, 6) 0.245
RESP score 0 (−2, 2) 0 (−2, 2) 0 (−2, 2) 1(−1, 3) 0.497
Etiology of ARF 0.001
Viral pneumonia 7 (6.7) 8 (8.0) 11 (8.5) 21 (13.7)
Bacterial pneumonia 33 (31.7) 16 (16.0) 37 (28.5) 41 (26.8)
COPD and asthma 1 (1.0) 2 (2.0) 4 (3.1) 1 (0.7)
Trauma and burn 1 (1.0) 4 (4.0) 10 (7.7) 10 (6.5)
Asphyxia 0 (0.0) 3 (3.0) 8 (6.2) 2 (1.3)
Acute exacerbation of ILD 8 (7.7) 17 (17.0) 13 (10.0) 23 (15.0)
Chronic respiratory failure 11 (10.6) 4 (4.0) 6 (4.6) 3 (2.0)
ARDS 13 (12.5) 14 (14.0) 7 (5.4) 10 (6.5)
Airway obstruction 10 (9.6) 6 (6.0) 4 (3.1) 8 (5.2)
Other respiratory failure 20 (19.2) 26 (26.0) 30 (23.1) 34 (22.2)
Immunocompromiseda 26 (25.2) 21 (21.4) 34 (26.2) 41 (26.8) 0.799
CNS dysfunctionb 3 (2.9) 3 (3.1) 8 (6.2) 10 (6.5) 0.413
Vasopressor 48 (46.2) 59 (59.0) 96 (75.6) 98 (66.7) < 0.001
Corticosteroid 22 (21.2) 21 (21.0) 23 (17.7) 16 (10.5) 0.068
Cardiac arrest 8 (7.7) 19 (19.0) 24 (18.5) 23 (15.0) 0.080
CRRT 20 (19.2) 19 (19.0) 20 (15.4) 24 (15.7) 0.783
Mechanical ventilation 94 (90.4) 83 (83.0) 125 (96.2) 147 (96.1) < 0.001
Prone positioning 7 (6.8) 3 (3.1) 58 (44.6) 75 (49.0) < 0.001
Pre-ECMO rescue therapy
Nitric oxide 29 (28.2) 22 (22.4) 42 (32.3) 34 (22.2) 0.197
Bicarbonate infusion 11 (10.7) 12 (12.2) 14 (10.8) 16 (10.5) 0.975
Neuromuscular blocker 29 (28.2) 32 (32.7) 80 (61.5) 89 (58.2) < 0.001
Values expressed as median (interquartile range), mean ± standard deviation, or n (%)
ECMO extracorporeal membrane oxygenation, APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, PRESERVE
Predicting Death for Severe Acute Respiratory Distress Syndrome on Veno-venous ECMO, RESP Respiratory Extracorporeal Membrane Oxygenation Survival
Prediction, ARF acute respiratory failure, COPD chronic obstructive pulmonary disease, ILD interstitial lung disease, ARDS acute respiratory distress syndrome,
CNS central nervous system, CRRT continuous renal replacement therapy
a“Immunocompromised” included hematological malignancies, solid tumors, solid-organ transplantation, high-dose or long-term corticosteroid and/or
immunosuppressant use, and human immunodeficiency virus infection
b“CNS dysfunction” included diagnoses of neurotrauma, stroke, encephalopathy, cerebral embolism, seizure, and epileptic syndrome
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ECMO-supported respiratory failure patients in Korea is
lower than the reported rate of 58% in the ELSO registry
[7]. Meanwhile, an ECMO epidemiologic study per-
formed in Germany reported that from 2012 to 2014 the
in-hospital survival had steadily increased and the rate
of survival was approximately 40%, which is similar to
our findings [8]. In addition, Sauer et al. [9] reported
that in the United States the survival rate of the patients
who received ECMO was approximately 40%. In the
German study, approximately 80% of patients were older
than 40 years and increasing numbers of older patients
had received ECMO. In the US study, the mean age of
the patients who received ECMO was 50 years, which
is higher than that of the patients included in the
ELSO registry. Taken together, the discrepancies in
demographics between the patients of ECMO centers
not included in the ELSO and those in the ELSO regis-
try may explain the difference in survival rates. Also,
another explanation for the relatively low survival rate
of Korean ECMO patients could be the infrequent use
of prone positioning. The use of prone positioning and
use of neuromuscular blockers were low compared
with those in the EOLIA trial [6], in which prone posi-
tioning was applied in 90% of patients in the conven-
tional ventilator support group, who showed a 54%
survival rate. The relatively low survival rate in Korean
ECMO patients may be due to excessive use of ECMO
in patients who may have shown good response to
Table 3 Pre-ECMO parameters of patients supported with ECMO for respiratory failure
Variable 2012 (n = 104) 2013 (n = 100) 2014 (n = 130) 2015 (n = 153) p value
Vital signs
MAP (mmHg) 74 (62, 89) 72 (59, 86) 63 (56, 72) 70 (57, 84) 0.001
Heart rate (/min) 112 (98, 125) 116 (101, 131) 107 (94, 125) 112 (94, 129) 0.462
Respiratory rate (/min) 26 (20, 30) 24 (20, 30) 20 (16, 26) 20 (16, 26) < 0.001
ECMO type 0.003
Veno-venous 96 (92.3) 95 (95.0) 113 (86.9) 125 (81.7)
Veno-arterial 4 (3.8) 2 (2.0) 11 (8.5) 25 (16.3)
Veno-arteriovenous 3 (2.9) 2 (2.0) 6 (4.6) 3 (2.0)
Other 1 (1.0) 1 (1.0) 0 (0.0) 0 (0.0)
Arterial blood gases
pH 7.31 (7.17, 7.43) 7.25 (7.17, 7.36) 7.26 (7.15, 7.37) 7.29 (7.18, 7.38) 0.081
PaO2 (mmHg) 60 (52, 74) 66 (56, 79) 62 (50, 75) 61 (46, 76) 0.211
PaCO2 (mmHg) 52 (40, 62) 56 (41, 72) 51 (39, 71) 47 (36, 59) 0.013
HCO3
− (mEq/L) 24.3 (21.1, 31.0) 24.1 (19.9, 29.5) 22.4 (18.1, 27.9) 22.0 (18.2, 25.5) 0.003
SaO2 (%) 88 (83, 92) 89 (85, 94) 88 (79, 93) 87 (75, 93) 0.243
Ventilation parameters
PaO2/FiO2 62 (53, 80) 72 (59, 96) 65 (53, 90) 65 (48, 97) 0.131
FiO2 100 (100, 100) 100 (90, 100) 100 (80, 100) 100 (80, 100) 0.069
PEEP (cmH2O) 10 (6, 12) 8 (5, 12) 10 (6, 10) 10 (7, 12) 0.119
PIP (cmH2O) 28 (24, 33) 30 (25, 34) 28 (23, 33) 28 (24, 31) 0.382
Tidal volume (ml/kg) 389 (298, 575) 420 (321, 513) 444 (340, 600) 428 (299, 518) 0.255
Driving pressure (cmH2O) 18 (14, 24) 20 (16, 25) 18 (15, 23) 18 (15, 21) 0.077
Minute ventilation (L/min) 10.9 (7.8, 14.6) 9.6 (7.7, 12.7) 9.5 (7.2, 12.2) 9.3 (6.8, 12.0) 0.035
Interval MV–ECMO (days) 2 (0, 7) 1 (0, 5) 1 (0, 5) 2 (0, 5) 0.090
ECMO duration (days) 7 (4, 14) 8 (5, 22) 8 (3, 13) 7 (4, 24) 0.305
Hospital stay (days) 32 (17, 47) 34 (19, 65) 39 (18, 73) 34 (17, 60) 0.318
Tracheostomy 32 (30.8) 38 (38.0) 61 (48.8) 68 (46.3) 0.023
Weaning rate 56 (53.8) 50 (50.0) 86 (66.2) 86 (56.2) 0.075
Survival rate 32 (30.8) 35 (35.0) 67 (51.5) 55 (35.9) 0.005
Values expressed as mean ± standard deviation, or n (%)
ECMO extracorporeal membrane oxygenation, MAP mean arterial pressure, PaO2 partial pressure of oxygen, PaCO2 partial pressure of carbon dioxide, HCO3
−
bicarbonate, SaO2 oxygen saturation, FiO2 fraction of inspired oxygen, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure,
MV mechanical ventilation
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Table 4 Univariate and multivariate analyses for mortality of ECMO
Variable OR (95% CI) p value OR (95% CI) p value
Age (years) 1.043 (1.029, 1.056) < 0.001 1.038 (1.022, 1.054) < 0.001
Male 0.720 (0.487, 1.064) 0.099
Year 0.645 (0.444, 0.939) 0.022
Body mass index (kg/m2) 0.982 (0.927, 1.040) 0.527
APACHE II score 1.032 (1.010, 1.054) 0.004
SOFA score 1.020 (0.978. 1.065) 0.358
Immunocompromised 1.335 (0.868, 2.054) 0.188
CNS dysfunction 1.274 (0.534, 3.038) 0.585
Vasopressor 1.254 (0.857, 1.836) 0.243
Corticosteroid 1.914 (1.130, 3.242) 0.016 2.251 (1.153, 4.397) 0.018
Cardiac arrest 1.050 (0.630, 1.747) 0.852
CRRT 2.102 (1.233, 3.581) 0.006 2.196 (1.135, 4.247) 0.019
Prone positioning 1.054 (0.705, 1.575) 0.798
Nitric oxide 1.853 (1.194, 2.875) 0.006
Bicarbonate infusion 1.521 (0.820, 2.820) 0.183
Neuromuscular blocker 1.186 (0.821, 1.711) 0.363
VV ECMO mode 0.810 (0.456, 1.439) 0.472
pH 0.800 (0.244, 2.618) 0.712
PaO2 (mmHg) 0.998 (0.993, 1.003) 0.433
PaCO2 (mmHg) 1.007 (0.999, 1.015) 0.083
PaO2/FiO2 0.999 (0.996, 1.002) 0.447
PEEP (cmH2O) 0.968 (0.918, 1.020) 0.219
PIP (cmH2O) 1.070 (1.034, 1.107) < 0.001
Tidal volume (ml/kg) 0.999 (0.998, 1.000) 0.175
Driving pressure (cmH2O) 1.078 (1.039, 1.118) < 0.001 1.072 (1.031, 1.114) < 0.001
Minute ventilation (L/min) 1.022 (0.969, 1.077) 0.428
Interval MV–ECMO (days) 1.024 (0.998, 1.050) 0.068
ECMO duration (days) 1.016 (1.003, 1.029) 0.017 1.020 (1.003, 1.038) 0.021
ECMO extracorporeal membrane oxygenation, OR odds ratio, CI confidence interval, APACHE Acute Physiology and Chronic Health Evaluation, SOFA Sequential
Organ Failure Assessment, CNS central nervous system, CRRT continuous renal replacement therapy. VV veno-venous, PaO2 partial pressure of oxygen,
PaCO2 partial pressure of carbon dioxide, FiO2 fraction of inspired oxygen, PEEP positive end-expiratory pressure, PIP peak inspiratory pressure,
MV mechanical ventilation
Fig. 2 Survival rates of ECMO patients according to age (years) (p< 0.001) and ECMO duration (p= 0.001). ECMO extracorporeal membrane oxygenation
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prone positioning. Accordingly, the use of prone posi-
tioning is gradually increasing in Korea.
Another interesting finding of our study was that the
survival rate was associated with the ECMO duration. The
survival rate of patients who required prolonged ECMO
(longer than 14 days) was significantly lower than that of
patients who had shorter ECMO duration (28% vs 43%,
respectively, p = 0.001). Recently, Posluszny et al. [19] re-
ported that ECMO duration was inversely correlated with
the survival rate in ECMO-supported patients with re-
spiratory failure; the survival rate in patients who had lon-
ger ECMO duration was 10% lower than that in those
with shorter ECMO duration. Nonetheless, the investiga-
tors suggested that prolonged ECMO was not futile be-
cause there was a significant improvement in survival
from 37% to 49% in recent years. On the other hand, the
aforementioned German epidemiologic study reported
that prolonged ECMO was associated with poorer out-
come; that the survival rate rapidly declined to 20% within
10 days after ECMO initiation [8]. Therefore, further stud-
ies are needed to provide a more solid association between
ECMO duration and the survival rate.
Our study has several limitations. This study was
retrospective and had a relatively short study period. Be-
cause not all patients treated with ECMO for respiratory
failure in Korea were included, selection bias is possible.
In addition, long-term outcomes and quality of life could
not be assessed, which warrants an extended observation
period of our study populations or further epidemiologic
studies. Despite such limitations, our current multicen-
ter study, which is not based on the ELSO registry, pro-
vides information on the change in the survival rate of
ECMO patients with respiratory failure and the factors
associated with survival, and adds to the understanding
of survival in patients who receive ECMO due to re-
spiratory failure.
Conclusions
This multicenter study performed in Korea showed that
utilization of ECMO for respiratory failure had increased
over time, and that the survival rates of ECMO-supported
respiratory failure patients had improved with increasing
utilization of adjunctive management. Patient age and dur-
ation of ECMO were significantly associated with survival
at discharge.
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